In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|September 2, 2021
Switzerland-Based CDMO ten23 health Launches
Author(s)BioPharm International Editors
CDMO ten23 health aims to support companies developing injectable biopharmaceutical drugs.
Advertisement
A new global contract development and manufacturing organization, ten23 health, announced its launch on Sept. 1, 2021. Financed through the 3i group, the company aims to support biotech start-ups and established pharmaceutical customers in developing safe injectable biopharmaceutical drugs.
The company will be headquartered out of a 4000 m² shared lab and office building in Basel, Switzerland, which will provide space for approximately 150 full-time employees. According to the press release, ten23 health intends to offer holistic design and development services with specific service offerings, including development roadmaps, de-risking strategies, and support throughout execution.
“There is a significant unmet need in the life sciences market,” said CEO Hanns–Christian Mahler in a company press release. “The number and complexity of molecules and novel therapeutic modalities are increasing. Medical research is facing growing challenges with respect to the stability, usability, and consistent manufacturing of medicines.”
The company is named after the Avogadro constant, a numeric value for the number of molecules in a sample of one mol: 6.022 times 1023.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5